Skip to main
WGS
WGS logo

WGS Stock Forecast & Price Target

WGS Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 67%
Buy 11%
Hold 22%
Sell 0%
Strong Sell 0%

Bulls say

GeneDx Holdings Corp has demonstrated substantial growth in its core exome/genome revenue, reporting a remarkable 65% year-over-year increase, which is indicative of robust demand and effective sales strategies. The company's anticipated volume shift towards exome/genome-based panels is projected to enhance average selling prices (ASPs) and gross margins (GMs), with GMs expected to reach 70%-71%, bolstered by a 23% year-over-year increase in core ASPs to $3,850 per test. Furthermore, GeneDx's upward revision of its 2025 revenue guidance to a range of $425-428 million, representing a 39%-40% year-over-year growth, underscores the company's positive outlook and strong market positioning within the precision medicine sector.

Bears say

GeneDx Holdings faces significant financial challenges, with an anticipated quarterly cash burn of approximately $2 million attributed to its Fabric initiative. The company is experiencing a high denial rate of 45% as of Q3'24 despite being contracted with around 80% of health plans, which raises concerns about its ability to secure adequate reimbursement for its genomic testing services. Additionally, the reliance on a limited supply of sequencers and materials, along with potential disruptions in data services, could severely impact GeneDx's operational and financial stability going forward.

WGS has been analyzed by 9 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 11% recommend Buy, 22% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of GeneDx Holdings Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About GeneDx Holdings Corp (WGS) Forecast

Analysts have given WGS a Buy based on their latest research and market trends.

According to 9 analysts, WGS has a Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $129.22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $129.22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

GeneDx Holdings Corp (WGS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.